Meeting
2024 ASCO Breakthrough
Real-world outcomes with lurbinectedin in second-line and beyond for small cell lung cancer in Korea.
Authors
Joosung Gabriel Shim
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea
Joosung Gabriel Shim , Sun Min Lim , Byoung Chul Cho , Min Hee Hong , Jii Bum Lee
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Thoracic Cancers,Breast Cancer,Gynecologic Cancer,Head and Neck Cancer,Hematologic Malignancies,Genetics/Genomics/Multiomics,Healthtech Innovations,Models of Care and Care Delivery,Viral-Mediated Malignancies,Other Malignancies or Topics
Sub Track
Real-World Evidence/Real-World Data
Citation
J Clin Oncol 42, 2024 (suppl 23; abstr 211)
DOI
10.1200/JCO.2024.42.23_suppl.211
Abstract #
211
Poster Bd #
K6
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
RESILIENT part I, an open-label, safety run-in of liposomal irinotecan in adults with small cell lung cancer (SCLC) who have progressed with platinum-based first-line (1L) therapy: Subgroup analyses by platinum sensitivity.
First Author: David R. Spigel
Poster
2023 ASCO Annual Meeting
Efficacy and safety of lurbinectedin in elderly patients with relapsed SCLC.
First Author: Sophie Cousin
Poster
2022 ASCO Annual Meeting
Efficacy and safety of lurbinectedin as second-line therapy in Chinese patients with small cell lung cancer: Preliminary results of a phase 1 study.
First Author: Ying Cheng
Poster
2022 ASCO Annual Meeting
Combi-TED: A multicenter, phase II, open-label, randomized trial evaluating efficacy of OSE2101 plus docetaxel or OSE2101 plus nivolumab as second-line therapy in metastatic NSCLC progressing after first-line chemo-immunotherapy.
First Author: Federico Cappuzzo